Inhibition of Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase 2 (MK2) is Protective in Pulmonary Hypertension

Hypertension. 2021 Apr;77(4):1248-1259. doi: 10.1161/HYPERTENSIONAHA.120.15229. Epub 2021 Mar 1.

Abstract

[Figure: see text].

Keywords: cardiovascular diseases; hypoxia; inflammation; mitogen-activated protein kinase; monocrotaline; pulmonary hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cell Proliferation
  • Cells, Cultured
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hypertension, Pulmonary* / metabolism
  • Hypertension, Pulmonary* / physiopathology
  • Hypertension, Pulmonary* / therapy
  • Hypoxia / metabolism
  • Inflammation / metabolism
  • Intracellular Signaling Peptides and Proteins* / antagonists & inhibitors
  • Intracellular Signaling Peptides and Proteins* / metabolism
  • Muscle, Smooth, Vascular / metabolism*
  • Oxidative Stress / drug effects
  • Peptides / pharmacology*
  • Protein Serine-Threonine Kinases* / antagonists & inhibitors
  • Protein Serine-Threonine Kinases* / metabolism
  • Pulmonary Artery* / metabolism
  • Pulmonary Artery* / physiopathology
  • Rats
  • Rats, Sprague-Dawley
  • Vascular Remodeling / drug effects

Substances

  • Enzyme Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • MMI-0100
  • Peptides
  • MAP-kinase-activated kinase 2
  • Protein Serine-Threonine Kinases